Thursday, February 2, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

Urgent Phase I/II Clinical Trial Funding to Repurpose Existing Therapeutics to Treat COVID-19

by Global Biodefense Staff
August 6, 2020
GSK Announces Plans to Produce 1 Billion Doses of Pandemic Vaccine Adjuvant in 2021

The National Institutes of Health has issued an urgent funding opportunity announcement to invite applications to repurpose existing therapeutic agents to treat Coronavirus Disease 2019 (COVID-19) sequelae and associated complications that result from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections. The therapeutic agent must have already completed at least a Phase I clinical trial for a different indication, and not require additional regulatory studies for the new indication prior to starting a clinical trial.

This initiative will support early stage clinical trials (through Phase II) on existing therapeutic agents that are already marketed or have been tested in humans in another Phase I clinical trial prior to application submission. The proposed clinical trials must use a readily available formulation for which preclinical safety studies have already been completed. Definitions of clinical trials for the purpose of this funding opportunity are as follows:

Phase I clinical studies: Studies conducted in the target patient population (e.g. 20-80) and healthy volunteers, where the purpose is to evaluate safety, determine a safe dose range, and identify side effects prior to conducting a Phase II clinical trial.

Phase II clinical studies: The therapeutic agent is given to a larger group of people (100–300) to determine its efficacy and to further study its safety.

Prospective applicants should not propose testing a therapeutic agent that significantly duplicates what already is being or has been clinically tested for COVID-19 sequelae and associated complications that result from SARS-CoV-2 infections prior to an NIH award being made.

Projects on novel targets will be a higher priority for support than projects that propose using a study drug that is already publicly posted anywhere in the world as already being clinically tested in COVID-19 patients.

Additional details are available at Grants.gov: RFA-TR-20-003. Applications are due by Jan 23, 2021.

Tags: AntiviralsClinical TrialsCOVID-19Drug DevelopmentEditor PickOpportunitiesRequest for ProposalsTherapeutic Antibodies

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
research team gathers in front of a window
CBRNE

UAMS Receives $3.4 Million to Study Radiation Injuries Caused by Nuclear Accidents and Bioterrorism

August 24, 2022
NIH to Further Invest in Point-of-Care Technologies Research Network
Biodetection

NIH to Further Invest in Point-of-Care Technologies Research Network

May 10, 2022
Supplemental Funding for Research at NIAID Regional Biocontainment Laboratories
Biosecurity

Supplemental Funding for Research at NIAID Regional Biocontainment Laboratories

May 5, 2022
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy